Bempikibart Shows Sustained Hair Regrowth in Alopecia Areata
Phase 2a trial data presented at AAD 2025 show bempikibart leads to sustained hair regrowth in severe alopecia areata, demonstrating for the first time an IL-7Rα antagonist approach.
Phase 2a trial data presented at AAD 2025 show bempikibart leads to sustained hair regrowth in severe alopecia areata, demonstrating for the first time an IL-7Rα antagonist approach.
The FDA has cleared Merz Aesthetics’ Ultherapy PRIME to improve the appearance of skin laxity on the knees, expanding the device’s body indications.